---
title: "iRadimed Non-GAAP EPS of $0.82, revenue of $1.19B; initiates FY25 outlook"
date: "2025-02-13 16:07:48"
summary: "iRadimed press release (NASDAQ:IRMD): Q4 Non-GAAP EPS of $0.82. Revenue of $1.19B (-3.3% Y/Y). Q4 adjusted EBITDA of $43.5 million, up 34% versus the prior year; adjusted EBITDA margin increased 110 basis points versus the prior year period to 3.7%. The company expects to deliver incremental organic revenue growth and..."
categories:
  - "seekalpha"
lang:
  - "en"
translations:
  - "en"
tags:
  - "seekalpha"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

* iRadimed [press release](https://seekingalpha.com/pr/20001285-kelly-reports-fourth-quarter-and-full-year-2024-earnings) (NASDAQ:[IRMD](https://seekingalpha.com/symbol/IRMD "IRADIMED CORPORATION")): Q4 Non-GAAP EPS of $0.82.
* Revenue of $1.19B (-3.3% Y/Y).
* Q4 adjusted EBITDA of $43.5 million, up 34% versus the prior year; adjusted EBITDA margin increased 110 basis points versus the prior year period to 3.7%.
* The company expects to deliver incremental organic revenue growth and adjusted EBITDA margin expansion during fiscal 2025.
* Announces planned retirement of president and chief executive officer Peter Quigley by the end of 2025.
* **Financial Outlook\*:**
  
  **First Half 2025:**
  
  + *Revenue* – total Company first half revenue up approximately 10% due to the benefit of the MRP acquisition, up modestly on an organic basis
    - Total Company revenue growth will be slightly higher in Q1 than in Q2 given the May 31, 2024 MRP transaction closing date
  + *GP rate* – total Company rate up approximately 80 basis points reflecting the benefit of the MRP acquisition; organic GP rate roughly flat
  + *Adjusted SG&A* – increase modestly on a quarterly run rate basis relative to Q4 2024, includes impact of payroll tax and performance-based incentive resets
    - Total D&A of approximately $13.5 million per quarter expected
  + *Adjusted EBITDA margin* – up 10 basis points to approximately 3.6%
  + *Tax rate* – effective rate in the high teens

[seekalpha](https://seekingalpha.com/news/4407633-iradimed-non-gaap-eps-of-082-revenue-of-119b-iniitates-fy25-outlook)
